AdAlta presented a poster at the 11th CAR-TCR Summit in Boston, highlighting our "East to West" model and lead asset EW-001 for advanced mesothelioma. The United States is the world’s largest market for cell therapies and home to most of the large pharmaceutical companies and specialist investors that AdAlta expects to be the ultimate buyers of its products. Building awareness of AdAlta’s assets and its differentiated, capital efficient model among these groups supports both the future on-licensing of EW-001 and the Company’s ability to fund and scale its pipeline.